Several studies have shown that sodium-glucose cotransporter-2 (SGLT2) inhibitors, peroxisome proliferator-activated receptor (PPAR) agonists, farnesoid X nuclear receptor (FXR) agonists, thyroid hormone receptor β (TR β) agonists and proprotein convertase subtilisin-kex in type 9 (PCSK9) inhibitors may be promising agents for the treatment of MAFLD patients with CKD [35,45]. Here, SLC5A2 is linked to chronic kidney disease.